What is claimed is:

1. A combination comprising a human anti-PD-L1 antibody, an anti-CTLA-4 antibody, and concurrent chemoradiation therapy for use in a method of increasing the overall response rate (ORR) in a patient with SCLC.

2. A combination comprising a human anti-PD-L1 antibody, an anti-CTLA-4 antibody, and concurrent chemoradiation therapy for use in a method of increasing the disease control rate (DCR) in a patient with SCLC.

3. A combination comprising a human anti-PD-L1 antibody, an anti-CTLA-4 antibody, and concurrent chemoradiation therapy for use in the treatment of SCLC.

4. Use of a combination comprising a human anti-PD-L1 antibody, an anti-CTLA-4 antibody, and concurrent chemoradiation therapy in the manufacture of a medicament for use in a method of increasing the overall response rate (ORR) in a patient with SCLC.

5. Use of a combination comprising a human anti-PD-L1 antibody, an anti-CTLA-4 antibody, and concurrent chemoradiation therapy in the manufacture of a medicament for use in a method of increasing the disease control rate (DCR) in a patient with SCLC.

6. Use of a combination comprising a human anti-PD-L1 antibody, an anti-CTLA-4 antibody, and concurrent chemoradiation therapy in the manufacture of a medicament for use in the treatment of SCLC.

7. The combination for use according to any one of claims 1 to 3, or the use according to any one of claims 4 to 6, wherein the SCLC is limited stage.

8. The combination for use according to any one of claims 1 to 3 and 7, or the use according to any one of claims 4 to 7, wherein the chemoradiation therapy comprises 60 to 70 Gy in 30 to 35 fractions.

9. The combination for use or the use according to claim 8, wherein the chemoradiation therapy comprises 2 Gy/fraction, 5 fractions per week, over 6 to 7 weeks.

10. The combination for use according to any one of claims 1 to 3 and 7, or the use according to any one of claims 4 to 7, wherein the chemoradiation therapy comprises hyperfractionated radiation.

11. The combination for use or the use according to claim 10, wherein the hyperfractionated radiation comprises 45 Gy in 30 fractions.

12. The combination for use or the use according to claim 11, wherein the hyperfractionated radiation comprises 1.5 Gy/fractions, 2 fractions per day at least 6 hours apart, 10 fractions per week, over 3 weeks.

13. The combination for use according to any one of claims 1 to 3 and 7 to 12, or the use according to any one of claims 4 to 12, wherein the chemoradiation therapy comprises cisplatin and/or carboplatin and etoposide.

14. The combination for use according to any one of claims 1 to 3 and 7 to 13, or the use according to any one of claims 4 to 13, wherein the anti-CTLA-4 antibody is tremelimumab.

15. The combination for use according to any one of claims 1 to 3 and 7 to 14, or the use according to any one of claims 4 to 14, wherein the anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab.

16. The combination for use according to any one of claims 1 to 3 and 7 to 15, wherein 1500 mg of the human anti-PD-L1 antibody is to be administered to the patient intravenously every four weeks (Q4W).

17. The use according to any one of claims 4 to 15, wherein 1500 mg of the human anti-PD-L1 antibody is to be administered to the patient intravenously every four weeks (Q4W).

18. The combination for use according to any one of claims 1 to 3 and 7 to 16, wherein 75 mg of the anti-CTLA-4 antibody is to be administered to the patient intravenously every four weeks (Q4W).

19. The use according to any one of claims 4 to 15 and 17, wherein 75 mg of the anti-CTLA-4 antibody is to be administered to the patient intravenously every four weeks (Q4W).

20. The combination for use according to any one of claims 1 to 3, 7 to 16 and 18, or the use according to any one of claims 4 to 15, 17 and 19, wherein the anti-PD-L1 antibody and the anti-CTLA-4 antibody are to be administered on the first day of chemoradiation therapy.